Search Menu

Home
HTB
2017
November
24

24 November 2017

Contents

Antiretrovirals

Coformulated dolutegravir plus rilpivirine approved in US (Juluca)

Darunavir-based single pill FDC approved in EU (Symtuza)

HTB RSS

Early access

NICE guidelines on management of chronic pain: exercise but not opiods 9 April 2021
Bar opening in the US: 100 guests linked to at least 46 cases of COVID-19 9 April 2021
HTB: no. 4 – plus HIV and COVID-19 (1 April 2021) 1 April 2021
All early access reports

Current issues

April 2021
March 2021
February 2021
Back issues

Special report

HTB: no. 3 – plus HIV and COVID-19 (12 March 2021) 12 March 2021

More from HTB

Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage

Home

i-Base homepage

This website sets no cookies from us or anyone else.

Information on this website is provided by treatment advocates and offered as a guide only. Decisions about your treatment should always be taken in consultation with your doctor.

This site complies with the HONcode standard for trustworthy health information.

HIV i-BASE
About us - Contact - Cookies and privacy - Copyright waiver - Terms of use - Home
107 The Maltings, 169 Tower Bridge Road, London SE1 3LJ.
Tel + 44 (0) 208 616 2210. Email admin@i-base.org.uk
Registered charity no: 1081905. Company reg no: 3962064.

Search i-Base

Site navigation

Quick links: HIV positive; Advocate; Professional; Donate; Feedback

Advice and information: Q and A; Phoneline; Pocket info; Guides; HIV meds; Glossary

Research and conference reports: HTB; HTB South; Pipeline report

Publications and resources: Publications; Other resources; Translations; Slide sets; Order and subscribe

News and updates: News; Blogs

Advocates' network: UK-CAB; Training manual

i-Base: About us; Contact; Sitemap; Home

Find us on Facebook